A retrospective study on efficacy and safety of rivaroxaban and dalteparin for long-term treatment of venous thromboembolism in patients with lung cancer
JH Lee, D Hyun, CM Choi, JC Lee, WS Kim, YM Oh… - Respiration, 2019 - karger.com
Background: Standard therapy for cancer-associated venous thromboembolism (VTE) is low-
molecular-weight heparin. The use of direct oral anticoagulants for cancer-associated VTE
has increased; however, their efficacy and safety in lung cancer patients remain unclear.
Objectives: We examined the efficacy and safety of rivaroxaban compared with dalteparin for
cancer-associated VTE in patients with primary lung cancer. Methods: A single-center
retrospective study of 204 patients with primary lung cancer who were prescribed …
molecular-weight heparin. The use of direct oral anticoagulants for cancer-associated VTE
has increased; however, their efficacy and safety in lung cancer patients remain unclear.
Objectives: We examined the efficacy and safety of rivaroxaban compared with dalteparin for
cancer-associated VTE in patients with primary lung cancer. Methods: A single-center
retrospective study of 204 patients with primary lung cancer who were prescribed …
Efficacy and safety of rivaroxaban and dalteparin for long-term treatment of venous thromboembolism in lung cancer
이장호， 현동곤， 최창민， 이재철， 김우성… - 대한결핵및호흡기학회 …, 2018 - papersearch.net
Objectives: The standard therapy for cancer-associated venous thromboembolism (VTE) is
low-molecular-weight heparin. Direct oral anticoagulants are increasingly used for cancer-
associated VTE without clear evidence. We examined the efficacy and safety of rivaroxaban
compared with dalteparin for cancer-associated VTE in patients with primary lung cancer.
Methods: This study of 204 patients with primary lung cancer who were prescribed
rivaroxaban (N= 131) or dalteparin (N= 73) for VTE was performed. We examined a …
low-molecular-weight heparin. Direct oral anticoagulants are increasingly used for cancer-
associated VTE without clear evidence. We examined the efficacy and safety of rivaroxaban
compared with dalteparin for cancer-associated VTE in patients with primary lung cancer.
Methods: This study of 204 patients with primary lung cancer who were prescribed
rivaroxaban (N= 131) or dalteparin (N= 73) for VTE was performed. We examined a …
